Search results for "immunosuppressive agent"

showing 10 items of 282 documents

Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study

2004

BACKGROUND: Atopic dermatitis (AD) is a chronic allergic inflammatory disease, which manifests itself with eczematous skin lesions. OBJECTIVE: We compared the clinical efficacy of tacrolimus ointment (0.1%) given twice a day and oral cyclosporine (3 mg/kg) given once daily. Rescue medication for itching included cetirizine 10-20 mg (equal to one or two tables). METHODS: Thirty patients, aged 13-45 years (mean+/-SD 27.1+/-10.9), with a history of moderate-to-severe AD were randomized to treatments, 15 patients for each treatments. Assessment of efficacy was based on SCORAD, on scores of daily itching, erythema, interference with sleep, due to the skin condition and days without use of cetiri…

atopic dermatitiAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentErythemaImmunologyAdministration OralDermatitisSeverity of Illness IndexGastroenterologyDrug Administration ScheduleAtopicDermatitis AtopicOintmentsAtopyLeukocyte CountDouble-Blind MethodInternal medicinemedicineHumansImmunology and Allergy; oral cyclosporine; atopic dermatitis; randomized study [tacrolimus ointment]SCORADcetirizinetacrolimusmedicine.diagnostic_testatopic dermatitisbusiness.industryArea under the curveoral cyclosporineAtopic dermatitisImmunoglobulin EMiddle Agedmedicine.diseaseDermatologyTacrolimusCetirizineEosinophilstacrolimus ointment:CyclosporineFemaleOnset of actionmedicine.symptombusinessrandomized studyImmunosuppressive Agentsmedicine.drug
researchProduct

Comment to “Management of cytomegalovirus infection in inflammatory bowel diseases”

2012

.

cytomegaloviruHepatologybusiness.industryGastroenterologyInflammatory Bowel DiseasesAntiviral AgentsInflammatory bowel diseaseCytomegalovirus infectionCrohn DiseaseCytomegalovirus InfectionsImmunologyHumansMedicineColitis Ulcerativecytomegalovirus; Inflammatory bowel diseasebusinessGanciclovircytomegalovirusImmunosuppressive AgentsDigestive and Liver Disease
researchProduct

Cytomegalovirus and inflammatory bowel disease: Is there a link?

2006

The objective of this report is to give an overall view of the epidemiological, clinical, diagnostic and therapeutic features of Cytomegalovirus (CMV) infection in inflammatory bowel disease (IBD). A review of published reports on this topic was carried out, with particular attention paid to the selection of patients included in studies and the diagnostic methods employed. CMV is frequently associated with IBD. In some cases, CMV infection is associated with a poor outcome but it is not clear which patients are more likely to be affected and in which stage of the disease. The use of anti-viral therapy in IBD is controversial and an empirical study with controls is needed. The natural histor…

medicine.medical_specialtyAcquired Immunodeficiency Syndromebusiness.industryGastroenterologyCongenital cytomegalovirus infectionGeneral MedicineDiseasemedicine.diseaseInflammatory Bowel DiseasesInflammatory bowel diseaseAntiviral Agentsdigestive system diseasesNatural historyImmune systemEpidemiologyImmunologyCytomegalovirus InfectionsmedicineHumansTopic HighlightStage (cooking)Viral persistencebusinessImmunosuppressive Agents
researchProduct

Management of oral Graft versus Host Disease with topical agents: a systematic review

2015

Background: Oral Graft-versus-Host Disease (oGvHD) is a common complication of haematopoietic stem cell transplantation. Choosing the right topical application to be used intra orally can be a challenge. Consequently, the aim of this work is to review the effectiveness and safety of topical agents currently used in the management of the inflammatory mucosal lesions encountered in oGVHD. Material and Methods: We carried out electronic searches of publications up to May 2015 of the databases Pubmed, National Library of Medicine’s Medline, Embase and the Cochrane Central Register of Controlled Clinical trials to identify potentially relevant studies (keywords: “oral”, “graft”, “versus”, “host”…

medicine.medical_specialtyAdministration TopicalGraft vs Host DiseaseOdontologíaReviewDisease03 medical and health sciences0302 clinical medicinemedicineHumansIntensive care medicineGlucocorticoidsGeneral Dentistrybusiness.industryMucosal lesions030206 dentistryMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryTransplantationGraft-versus-host diseaseOtorhinolaryngologyTopical agents030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryStem cellMouth DiseasesbusinessComplicationImmunosuppressive Agents
researchProduct

Postoperative maintenance therapy for inflammatory bowel disease.

2006

. Curr Opin Gastroenterol. 2006 Jul;22(4):377-81. Postoperative maintenance therapy for inflammatory bowel disease. Cottone M, Orlando A, Modesto I. Department of General Medicine, Pneumology and Nutrition Clinic, Palermo University, Palermo, Italy. PURPOSE OF REVIEW: This review will highlight the knowledge gained from studies published in the year 2005 on maintenance treatment after surgery for inflammatory bowel diseases. RECENT FINDINGS: In Crohn's disease the role of smoking in increasing the risk of relapse and recurrence after surgery is confirmed. Ornidazole seems effective in reducing endoscopic recurrence and clinical relapse after surgery. Probiotics do not appear to be effective…

medicine.medical_specialtyAzathioprineInflammatory bowel diseaseEnteral NutritionMaintenance therapymedicineHumansIntensive care medicineDigestive System Surgical Procedurescrohn.post-operative.Postoperative CareCrohn's diseasebusiness.industryProbioticsGastroenterologyRetrospective cohort studyPouchitismedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisSurgeryAnti-Bacterial AgentsParenteral nutritionTreatment OutcomebusinessImmunosuppressive Agentsmedicine.drugCurrent opinion in gastroenterology
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission in…

2019

Treatment of vasculitides associated with anti-neutrophil cytoplasm antibodies (ANCA) (AAVs) has evolved dramatically in recent years, particularly since the demonstration of rituximab efficacy as remission induction and maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. In 2013, the French Vasculitis Study Group (FVSG) published recommendations for its use by clinicians. Since then, new data have made it possible to better specify and codify prescription of rituximab to treat AAVs. Herein, the FVSG Recommendations Committee, an expert panel comprised of physicians with extensive experience in the treatment and management of vasculitides, presents its con…

medicine.medical_specialtyCardiologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMaintenance Chemotherapy03 medical and health sciencesRemission induction0302 clinical medicineMaintenance therapymedicineHumans030212 general & internal medicineMedical prescriptionIntensive care medicineSocieties Medical030203 arthritis & rheumatologybusiness.industryRemission InductionGranulomatosis with PolyangiitisGeneral Medicinemedicine.diseaseBiological TherapyPractice Guidelines as TopicRituximabFranceGranulomatosis with polyangiitisbusinessMicroscopic polyangiitisVasculitisMepolizumabImmunosuppressive Agentsmedicine.drugLa Presse Médicale
researchProduct

An update on medical management on Crohn's disease.

2014

The management of Crohn's disease (CD) is continuously evolving. New issues emerging from more recent studies could influence the decision-making process in clinical practice.The aim of this review article is to highlight critical issues on the management of CD, new evidence from clinical trials, long-term prospective studies and real life experience, beyond the current guidelines.The role of mucosal healing in clinical practice is uncertain, clinical remission remains the primary end point. The timing for the definition of steroid-resistant CD should be considered between 2 and 4 weeks. Early treatment strategy with immunomodulators is effective for inducing remission but no controlled dat…

medicine.medical_specialtyCombination therapyAzathioprineDiseasechemistry.chemical_compoundMesalazineAdjuvants ImmunologicCrohn DiseaseClinical endpointMedicineHumansPharmacology (medical)Prospective StudiesIntensive care medicinePharmacologyCrohn's diseaseBiological ProductsClinical Trials as Topicbusiness.industryTumor Necrosis Factor-alphaRemission InductionGeneral Medicinemedicine.diseaseReview articleSurgeryClinical trialchemistryPractice Guidelines as TopicDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drugExpert opinion on pharmacotherapy
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct